Enhancing the intranasal delivery of mRNA therapeutics using a novel thermosensitive polymer

Written By PY

Click on image to read article

Discover how Ab Initio Pharma, in collaboration with Tetratherix, is advancing nasally inhaled biologics with a novel thermosensitive polymer (TP) for mRNA therapeutics. Presented by our COO, Hui Xin Ong, at the Drug Delivery to the Lungs 2024 conference, this case study highlights TP’s unique ability to transition from liquid to hydrogel at physiological temperature, enhancing nasal retention, stability, and efficacy. Learn how this innovative approach addresses challenges like mucociliary clearance and bioavailability, showcasing Ab Initio's leadership in cutting-edge drug delivery technologies.

PY
Next

Development and evaluation of nebulised oligonucleotide formulations for the treatment of chronic obstructive pulmonary disease.